On July 25, 2025, Tonix Pharmaceuticals disclosed preliminary financial results for Q2 2025, reporting $125.3 million in cash, a net loss of $26.3 million, and revenues of $2.0 million. The company expects its cash resources to meet operational needs through Q3 2026, following a recent equity raise of $50.6 million.